About 85% to 90% of the cases of age-related macular degeneration (AMD) are the “dry” (atrophic) type.
The year 2018 had its share of groundbreaking research in age-related macular degeneration (AMD). Here is a brief overview of what’s been presented or published within the past 12 months.
More and more companies are looking for novel ways to educate both eye-care professionals and patients about age-related macular degeneration (AMD).
Below are a few of the newer training materials available.
Age-related macular degeneration (AMD) affects more than 10 million Americans, and the risk of developing AMD is increased when there is a family history.
A signaling pathway controlled by transforming growth factor beta (TGF-beta) could be involved in the progression of age-related macular degeneration (AMD), according to a study.1
Numerous websites are designed to raise awareness about age-related macular degeneration (AMD), some sponsored by the National Eye Institute, others by disease-specific foundations, and others by industry.
Clinical trial data focusing on treatment for age-related macular degeneration (AMD) have been a highlight at many recent ophthalmology meetings. Here are a few of the latest clinical trials that physicians need to be aware.
Although a proven treatment therapy, age-related macular degeneration (AMD) requires frequent, costly anti-vascular endothelial growth factor (anti-VEGF) injections. Some pharmaceutical companies do have patient-assistance programs to help alleviate the financial burden.
Research on treatments and/or causes of age-related macular degeneration (AMD) covers a wide range of approaches and paradigms. The latest research published in the past three months are perfect examples for understanding and treating AMD.
Age-related macular degeneration (AMD) is the leading cause of significant visual acuity loss in people over the age of 50 in developed countries. Almost 80% of the people diagnosed with AMD will have the non-neovascular (dry) or atrophic subtypes. Here is the clinical information patients need to understand this disease.